| Size | Price | |
|---|---|---|
| Other Sizes |
Purity: Content≥99%
| Targets |
L-Ascorbic acid 2-phosphate itself does not have a specific pharmacological receptor target. Its function is to serve as a stable, non-oxidizable precursor that delivers L-ascorbic acid intracellularly. Once inside the cell, the phosphate group is cleaved by alkaline phosphatases, releasing active L-ascorbic acid. The active form functions as an essential cofactor for enzymes such as prolyl hydroxylases and lysyl hydroxylases.
|
|---|---|
| ln Vitro |
Cell growth was strongly enhanced by L-ascorbic acid 2-phosphate (0.1-1.5 mM; medium changes every 2–3 days for 2–3 weeks), but addition of L-ascorbic acid (Asc) only produced a mild growth stimulation. Cell growth is greatly enhanced by the combination of Asc-2P and bFGF; however, additional effects are not produced by the addition of EGF or insulin [1]. L-ascorbic acid 2-phosphate (50 µM–250 µM) is necessary for the efficient osteogenic differentiation of human adipose stem cells (hASCs), and AsA2-P concentrations greater than 50 µM cause an increase in runx2 expression and ALP activity. The combinations of 150 µM asA2-P and 10 nM dexamethasone (Dex) and 250 µM asA2-P and 5 nM Dex produced the maximum proliferation, ALP activity, and runx2 expression [3].
In vitro, L-ascorbic acid 2-phosphate is used as a supplement in cell culture at concentrations of 50-100 µg/mL to promote collagen synthesis and cell proliferation. It enhances osteoblast differentiation and mineralization at concentrations of 0.1-1 mM. The compound exhibits antioxidant activity by neutralizing free radicals after conversion to L-ascorbic acid. It also stimulates keratinocyte differentiation in skin cells. |
| ln Vivo |
In vivo, L-ascorbic acid 2-phosphate magnesium serves as a source of vitamin C. In animal models of vitamin C deficiency (e.g., guinea pigs), oral administration at doses of 10-50 mg/kg effectively prevents scurvy and normalizes collagen metabolism. It promotes wound healing and bone formation. The compound has been tested in cosmetic applications for skin whitening and anti-aging effects.
|
| Enzyme Assay |
No specific in vitro enzyme binding assay is applicable for L-ascorbic acid 2-phosphate itself. The compound is typically used as a reagent in cell culture media. Quality control assays include alkaline phosphatase conversion: the compound is incubated with alkaline phosphatase, and the release of inorganic phosphate is quantified by a colorimetric assay (ammonium molybdate method) at 820 nm. Purity analysis is performed by HPLC with UV detection at 254 nm.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: human corneal endothelial cells (HCEC) Tested Concentrations: 0.1 mM; 0.3 mM; 1.5 mM Incubation Duration: 2 to 3 weeks, medium replacement every 2 to 3 days Experimental Results: Stimulated HCEC cell growth. For in vitro cell culture studies, L-ascorbic acid 2-phosphate magnesium is dissolved in culture medium (DMEM or α-MEM) at concentrations of 50-200 µg/mL. Cells such as MC3T3-E1 osteoblasts or human dermal fibroblasts are seeded in 24-well plates and cultured in the presence of the compound for 7-21 days. Collagen synthesis is assessed by hydroxyproline content assay. Alizarin red S staining is used to evaluate mineralization in osteogenic differentiation studies. |
| Animal Protocol |
In vivo animal studies are typically performed in guinea pigs or other animal models that cannot synthesize vitamin C. Guinea pigs (300-400 g) are fed a vitamin C-deficient diet for 3 weeks until signs of scurvy appear. L-Ascorbic acid 2-phosphate magnesium is then administered orally at doses of 5, 20, and 50 mg/kg for 2 weeks. Body weight, clinical signs, and serum vitamin C levels are monitored. At sacrifice, liver and bone tissues are collected for histological analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for L-ascorbic acid 2-phosphate magnesium are similar to those of vitamin C. It is hydrolyzed to L-ascorbic acid in the gastrointestinal tract, and the released ascorbic acid is absorbed via SVCT1 transporters. The bioavailability of vitamin C from the phosphate derivative is approximately 70-80% compared to L-ascorbic acid in humans. The compound is distributed to all tissues and has a plasma half-life of 2-3 hours. It is excreted in urine and feces.
|
| Toxicity/Toxicokinetics |
L-Ascorbic acid 2-phosphate magnesium has very low toxicity. The oral LD50 in rats is >5000 mg/kg. It is not mutagenic, carcinogenic, or teratogenic. At high doses (5000 mg/kg), mild gastrointestinal disturbances may occur. The compound is considered safe for use in cosmetics and food supplements. No significant adverse effects have been reported in clinical or animal studies.
|
| References |
|
| Additional Infomation |
L-ascorbic acid-2-phosphate magnesium is an organic molecular entity.
L-Ascorbic acid 2-phosphate magnesium is a white to off-white powder with a molecular weight of 289.43 g/mol (anhydrous). It is highly soluble in water and practically insoluble in organic solvents. Unlike L-ascorbic acid, it is resistant to oxidation and retains its activity in culture media for extended periods. It is widely used in stem cell culture, tissue engineering, and cosmetic formulations. The compound is available as a research reagent and is not an approved drug. |
| Molecular Formula |
C₆H₉O₉P.₃/₂MG
|
|---|---|
| Molecular Weight |
292.56
|
| Exact Mass |
277.967
|
| CAS # |
113170-55-1
|
| Related CAS # |
L-Ascorbic acid 2-phosphate trisodium;66170-10-3;L-Ascorbic acid 2-phosphate;23313-12-4
|
| PubChem CID |
54679072
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
357
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C([C@@H]([C@@H]1C(=C(C(=O)O1)OP(=O)([O-])[O-])O)O)O.[Mg+2]
|
| InChi Key |
ACFGRWJEQJVZTM-LEJBHHMKSA-L
|
| InChi Code |
InChI=1S/C6H9O9P.Mg/c7-1-2(8)4-3(9)5(6(10)14-4)15-16(11,12)13;/h2,4,7-9H,1H2,(H2,11,12,13);/q;+2/p-2/t2-,4+;/m0./s1
|
| Chemical Name |
magnesium;[(2R)-2-[(1S)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2H-furan-4-yl] phosphate
|
| Synonyms |
LAscorbic acid 2phosphate magnesium; L Ascorbic acid 2 phosphate magnesium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~85.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4181 mL | 17.0905 mL | 34.1810 mL | |
| 5 mM | 0.6836 mL | 3.4181 mL | 6.8362 mL | |
| 10 mM | 0.3418 mL | 1.7091 mL | 3.4181 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA